Company: SUPN
Filing Date: 2025-07-31
Form Type: 8-K
Source: 0001104659-25-072506
Chunk: 0

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-07-31
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01      Entry into a Material Definitive Agreement.  

As previously disclosed in
the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “ SEC”) by Supernus Pharmaceuticals, Inc.,
a Delaware corporation (the “ Supernus”), on June 16, 2025, Supernus entered into an Agreement and Plan of Merger,
dated as of June 13, 2025 (the “ Merger Agreement”), with Sage Therapeutics, Inc., a Delaware corporation
(“ Company” or “ Sage”), and Saphire, Inc., a Delaware corporation and a wholly-owned subsidiary
of Supernus (“ Purchaser”). All capitalized terms used herein and not otherwise defined have the meanings given to such
terms in the Merger Agreement.

Pursuant to the Merger Agreement
and in connection with Purchaser’s acceptance of Shares tendered in the Offer for purchase, on July 30, 2025 the Company and
Equiniti Trust Company, LLC, as rights agent, entered into a contingent value rights agreement (the “CVR Agreement”)
to allow for the payment of the milestones payment(s) pursuant to each CVR (as defined below).